Research graph
References from MK-4002, a B-cell maturation antigen-targeting T-cell engager, in relapsed or refractory multiple myeloma: a first-in-human, open-label, phase 1 study. Local targets link to admitted publications; unresolved targets remain external evidence.
Diagnosis and management of multiple myeloma: a review
10.1001/jama.2022.0003 · 2022 · External reference
Multiple myeloma
10.1038/s41572-024-00529-7 · 2024 · External reference
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
10.1016/s1470-2045(20)30756-7 · 2021 · External reference
Updates on therapeutic strategies in the treatment of relapsed/refractory multiple myeloma
10.3390/cancers16172931 · 2024 · External reference
Relapsed/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse
10.3390/curroncol30020179 · 2023 · External reference
BCMA-targeted immunotherapy for multiple myeloma
10.1186/s13045-020-00962-7 · 2020 · External reference
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma
10.1038/s41408-024-01081-z · 2024 · External reference
HPN217-3001: a phase 1/2 open-label, multicenter, dose escalation and dose expansion study of the safety, tolerability, and pharmacokinetics of HPN217, a BCMA-targeting T-cell engager, in patients with relapsed/refractory multiple myeloma
10.1182/blood-2020-136012 · 2020 · External reference
Fc-engineering for modulated effector functions-improving antibodies for cancer treatment
10.3390/antib9040064 · 2020 · External reference
Preclinical and nonclinical characterization of HPN217: a tri-specific T cell activating construct (TriTAC) targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma
2018 · External reference
ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells
10.1016/j.bbmt.2018.12.758 · 2019 · External reference
International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders
10.1016/s1470-2045(19)30309-2 · 2019 · External reference
Revised international staging system for multiple myeloma: a report from International Myeloma Working Group
10.1200/jco.2015.61.2267 · 2015 · External reference
Bispecific antibodies in multiple myeloma: opportunities to enhance efficacy and improve safety
10.3390/cancers15061819 · 2023 · External reference
Management of adverse reactions for BCMA-directed therapy in relapsed multiple myeloma: a focused review
10.3390/jcm12175539 · 2023 · External reference
Teclistamab in relapsed or refractory multiple myeloma
10.1056/nejmoa2203478 · 2022 · External reference
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
10.1038/s41591-023-02528-9 · 2023 · External reference
Linvoseltamab for treatment of relapsed/refractory multiple myeloma
10.1200/jco.24.01008 · 2024 · External reference
HPN328, a trispecific T cell-activating protein construct targeting DLL3-expressing solid tumors
10.1158/1535-7163.mct-23-0524 · 2024 · External reference
Teclistamab: mechanism of action, clinical, and translational science
10.1111/cts.13717 · 2024 · External reference
Racial disparities in multiple myeloma
2025 · External reference
